Functionalized Imidazo[1,2-a]pyridine-3-yl Scaffolds: Synthetic Strategies and Anticancer Potential Agent

The imidazo[1,2 a]pyridine scaffold has emerged as a highly versatile platform in medicinal chemistry, attracting increasing attention due to its relevance in oncology. Over the past decade, significant progress has been made in the development of C3-functionalization strategies, which have broadened the chemical diversity accessible within this heterocyclic framework. This mini review aims to condense these advances and correlate the synthetic modifications introduced at the C3-position with reported in vitro anticancer activities. Representative synthetic methodologies are highlighted, including transition metal-catalyzed approaches, electrophilic substitution, and multicomponent reactions, each offering distinct advantages in terms of efficiency, selectivity, and structural diversity. Alongside these methods, emerging structure-activity relationships are discussed, emphasizing how subtle changes at the C3-position can modulate biological activity and improve potency against selected cancer cell lines. Despite encouraging advances with C3-modified imidazo[1,2 a]pyridines, critical knowledge gaps persist. Limited mechanistic studies, scarce ADME Tox profiling, and few in vivo evaluations restrict their preclinical validation. To fully exploit their therapeutic potential, future research should prioritize systematic assessment and expanded in vivo studies. Integrating synthetic innovation with biological insight will accelerate the translation of these scaffolds into viable preclinical candidates, reinforcing their promise in anticancer drug discovery.